Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 35 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BIOXODES from Charleroi, company number BE0825151779, closed financial year 2025 with a result of € -3.4 million after tax. For that financial year BIOXODES recorded a gross margin of € -112,453 and equity of € -1.7 million. Compared with financial year 2024, the result moved from € -4 million to € -3.4 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ -1.7 million
▼ € 4.5 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3.4 million
▲ 14 % less loss than in 2024
Profit after tax over the fiscal year.
€ 2 million
▲ 55% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.4 million.
People and assets in 2025
7.7
▼ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 16% vs 2024
€ 148,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 8,740
▼ 1% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 5.8 million
Loans from banks and other lenders, long and short.
€ 400,495
▼ 26% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 103,874
▼ 43% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 972,834 | € -1,689,044 | € -888,611 | € -112,453 | ▲ € 776,159 |
| Profit after taxes | € -2,004,162 | € -4,876,079 | € -4,017,938 | € -3,441,017 | ▲ € 576,921 |
| Equity | € 6,717,448 | € 6,920,247 | € 2,807,071 | € -1,662,624 | ▼ € 4.5 million |
| Total debts | € 2,246,315 | € 3,337,431 | € 4,183,156 | € 9,344,093 | ▲ 123% |
| Cash | € 3,656,110 | € 4,968,706 | € 1,317,706 | € 2,036,233 | ▲ 55% |
| Retained profit | € -175,189 | € -5,051,268 | € -9,069,206 | € -3,441,017 | ▲ € 5.6 million |
| Bank debt | € 636,033 | € 871,982 | € 0 | € 5,750,471 | |
| Balance sheet total | € 8,963,763 | € 10,257,678 | € 6,990,227 | € 7,681,469 | ▲ 10% |
| Employees (FTE) | 8.8 | 8.8 | 8.8 | 7.7 | ▼ 1.1 |
Key figures of BIOXODES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIOXODES?
What happened at BIOXODES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- XMF SRL stepped down as director. NBB
- PHMBIO+ SRL stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 3.4 million. Source: NBB ↗
- CROUGHS R&D CONSULTING AUTRE stepped down as director. NBB
- Capital & Croissance SCRL stepped down as director. NBB
- Société Fédérale de Participations et d' Investissements SA stepped down as director. NBB
- PHMBIO+ SRL became a director. NBB
- XMF SRL became a director. NBB
In short
From € 2 million loss in 2022 to € 3.4 million loss in 2025.
Paid € 4,941 in corporate taxes since 2022.
On average € 110,500 of value added per employee in 2022.
Management
The stake of SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT, INVESTSUD TECH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIOXODESThe shares are held by SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT (24.7%) and INVESTSUD TECH (14%).
Directors
According to the 2025 annual accounts
CROUGHS R&D CONSULTING AUTRE
Director · represented by Croughs Thérèse
since 2020 · until 2026
Director · represented by Pierre Detrixhe
Also active at: CONCEPTEXPO GROUP, COLONA, MEGAFORM, SUPERPLASTIC, SOCIETE COMMERCIALE ET INDUSTRIELLE, BAUWENS ROGER, SOGECAM, HORUS SOFTWARE +29 more
since 2020 · until 2026
Société Fédérale de Participations et d' Investissements SA
Director · represented by François Fontaine
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale, COMETSAMBRE, ASCO INDUSTRIES, ZEPHYR - FIN, Sabena Aerospace Engineering, reMYND +58 more
since 2020 · until 2026
Chairman of the board · represented by Monteyne Philippe
since 2025 · until 2026
Director · represented by Marc DECHAMPS
since 2022 · until 2028
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Santos - Dumont 1
6041 Charleroi
Rue Santos - Dumont 1-7
6041 Charleroi
Active since 20 April 2010
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0825.151.779
- VAT number
- BE 0825.151.779
- Registered office
- Rue Santos - Dumont 1, 6041 Charleroi
- Names & denominations
- BIOXODES
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 April 2010
- Peppol
- Active · Active since 21 Oct 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied